Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

Enrica Morra, Giovanni Barosi, Alberto Bosi, Felicetto Ferrara, Franco Locatelli, Monia Marchetti, Giovanni Martinelli, Cristina Mecucci, Marco Vignetti, Sante Tura

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

As many options are now available to treat patients with de novo acute myeloid leukemia, the Italian Society of Hematology and two affiliated societies (SIES and GITMO) commissioned a project to an Expert Panel aimed at developing clinical practice guidelines for acute myeloid leukemia treatment. After a systematic comprehensive literature review, the Expert Panel formulated recommendations for the management of primary acute myeloid leukemia (with the exception of acute promyelocytic leukemia) and graded them according to the supporting evidence. When evidence was lacking, consensus-based statements have been added. First-line therapy for all newly diagnosed patients eligible for intensive treatment should include one cycle of induction with standard dose cytarabine and an anthracycline. After achieving complete remission, patients aged less than 60 years should receive consolidation therapy including high-dose cytarabine. Myeloablative allogeneic stem cell transplantation from an HLA-compatible sibling should be performed in first complete remission: 1) in children with intermediate-high risk cytogenetics or who achieved first complete remission after the second course of therapy; 2) in adults less than 40 years with an intermediate-risk; in those aged less than 55 years with either high-risk cytogenetics or who achieved first complete remission after the second course of therapy. Stem cell transplantation from an unrelated donor is recommended to be performed in first complete remission in adults 30 years old or younger, and in children with very high-risk disease lacking a sibling donor. Alternative donor stem cell transplantation is an option in high-risk patients without a matched donor who urgently need transplantation. Patients aged less than 60 years, who either are not candidate for allogeneic stem cell transplantation or lack a donor, are candidates for autologous stem cell transplantation. We describe the results of a systematic literature review and an explicit approach to consensus techniques, which resulted in recommendations for the management of primary non-APL acute myeloid leukemia.

Original languageEnglish
Pages (from-to)102-112
Number of pages11
JournalHaematologica
Volume94
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Hematology
Bone Marrow Transplantation
Practice Guidelines
Acute Myeloid Leukemia
Stem Cell Transplantation
Tissue Donors
Cytarabine
Cytogenetics
Siblings
Consensus
Therapeutics
Unrelated Donors
Acute Promyelocytic Leukemia
Anthracyclines
Transplantation

Keywords

  • Acute myeloid leukemia
  • Clinical practice guidelines
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia : Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. / Morra, Enrica; Barosi, Giovanni; Bosi, Alberto; Ferrara, Felicetto; Locatelli, Franco; Marchetti, Monia; Martinelli, Giovanni; Mecucci, Cristina; Vignetti, Marco; Tura, Sante.

In: Haematologica, Vol. 94, No. 1, 01.2009, p. 102-112.

Research output: Contribution to journalArticle

Morra, Enrica ; Barosi, Giovanni ; Bosi, Alberto ; Ferrara, Felicetto ; Locatelli, Franco ; Marchetti, Monia ; Martinelli, Giovanni ; Mecucci, Cristina ; Vignetti, Marco ; Tura, Sante. / Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia : Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. In: Haematologica. 2009 ; Vol. 94, No. 1. pp. 102-112.
@article{822f2bacb9a64d3aa5d9f23ec40a1aa2,
title = "Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation",
abstract = "As many options are now available to treat patients with de novo acute myeloid leukemia, the Italian Society of Hematology and two affiliated societies (SIES and GITMO) commissioned a project to an Expert Panel aimed at developing clinical practice guidelines for acute myeloid leukemia treatment. After a systematic comprehensive literature review, the Expert Panel formulated recommendations for the management of primary acute myeloid leukemia (with the exception of acute promyelocytic leukemia) and graded them according to the supporting evidence. When evidence was lacking, consensus-based statements have been added. First-line therapy for all newly diagnosed patients eligible for intensive treatment should include one cycle of induction with standard dose cytarabine and an anthracycline. After achieving complete remission, patients aged less than 60 years should receive consolidation therapy including high-dose cytarabine. Myeloablative allogeneic stem cell transplantation from an HLA-compatible sibling should be performed in first complete remission: 1) in children with intermediate-high risk cytogenetics or who achieved first complete remission after the second course of therapy; 2) in adults less than 40 years with an intermediate-risk; in those aged less than 55 years with either high-risk cytogenetics or who achieved first complete remission after the second course of therapy. Stem cell transplantation from an unrelated donor is recommended to be performed in first complete remission in adults 30 years old or younger, and in children with very high-risk disease lacking a sibling donor. Alternative donor stem cell transplantation is an option in high-risk patients without a matched donor who urgently need transplantation. Patients aged less than 60 years, who either are not candidate for allogeneic stem cell transplantation or lack a donor, are candidates for autologous stem cell transplantation. We describe the results of a systematic literature review and an explicit approach to consensus techniques, which resulted in recommendations for the management of primary non-APL acute myeloid leukemia.",
keywords = "Acute myeloid leukemia, Clinical practice guidelines, Stem cell transplantation",
author = "Enrica Morra and Giovanni Barosi and Alberto Bosi and Felicetto Ferrara and Franco Locatelli and Monia Marchetti and Giovanni Martinelli and Cristina Mecucci and Marco Vignetti and Sante Tura",
year = "2009",
month = "1",
doi = "10.3324/haematol.13166",
language = "English",
volume = "94",
pages = "102--112",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia

T2 - Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

AU - Morra, Enrica

AU - Barosi, Giovanni

AU - Bosi, Alberto

AU - Ferrara, Felicetto

AU - Locatelli, Franco

AU - Marchetti, Monia

AU - Martinelli, Giovanni

AU - Mecucci, Cristina

AU - Vignetti, Marco

AU - Tura, Sante

PY - 2009/1

Y1 - 2009/1

N2 - As many options are now available to treat patients with de novo acute myeloid leukemia, the Italian Society of Hematology and two affiliated societies (SIES and GITMO) commissioned a project to an Expert Panel aimed at developing clinical practice guidelines for acute myeloid leukemia treatment. After a systematic comprehensive literature review, the Expert Panel formulated recommendations for the management of primary acute myeloid leukemia (with the exception of acute promyelocytic leukemia) and graded them according to the supporting evidence. When evidence was lacking, consensus-based statements have been added. First-line therapy for all newly diagnosed patients eligible for intensive treatment should include one cycle of induction with standard dose cytarabine and an anthracycline. After achieving complete remission, patients aged less than 60 years should receive consolidation therapy including high-dose cytarabine. Myeloablative allogeneic stem cell transplantation from an HLA-compatible sibling should be performed in first complete remission: 1) in children with intermediate-high risk cytogenetics or who achieved first complete remission after the second course of therapy; 2) in adults less than 40 years with an intermediate-risk; in those aged less than 55 years with either high-risk cytogenetics or who achieved first complete remission after the second course of therapy. Stem cell transplantation from an unrelated donor is recommended to be performed in first complete remission in adults 30 years old or younger, and in children with very high-risk disease lacking a sibling donor. Alternative donor stem cell transplantation is an option in high-risk patients without a matched donor who urgently need transplantation. Patients aged less than 60 years, who either are not candidate for allogeneic stem cell transplantation or lack a donor, are candidates for autologous stem cell transplantation. We describe the results of a systematic literature review and an explicit approach to consensus techniques, which resulted in recommendations for the management of primary non-APL acute myeloid leukemia.

AB - As many options are now available to treat patients with de novo acute myeloid leukemia, the Italian Society of Hematology and two affiliated societies (SIES and GITMO) commissioned a project to an Expert Panel aimed at developing clinical practice guidelines for acute myeloid leukemia treatment. After a systematic comprehensive literature review, the Expert Panel formulated recommendations for the management of primary acute myeloid leukemia (with the exception of acute promyelocytic leukemia) and graded them according to the supporting evidence. When evidence was lacking, consensus-based statements have been added. First-line therapy for all newly diagnosed patients eligible for intensive treatment should include one cycle of induction with standard dose cytarabine and an anthracycline. After achieving complete remission, patients aged less than 60 years should receive consolidation therapy including high-dose cytarabine. Myeloablative allogeneic stem cell transplantation from an HLA-compatible sibling should be performed in first complete remission: 1) in children with intermediate-high risk cytogenetics or who achieved first complete remission after the second course of therapy; 2) in adults less than 40 years with an intermediate-risk; in those aged less than 55 years with either high-risk cytogenetics or who achieved first complete remission after the second course of therapy. Stem cell transplantation from an unrelated donor is recommended to be performed in first complete remission in adults 30 years old or younger, and in children with very high-risk disease lacking a sibling donor. Alternative donor stem cell transplantation is an option in high-risk patients without a matched donor who urgently need transplantation. Patients aged less than 60 years, who either are not candidate for allogeneic stem cell transplantation or lack a donor, are candidates for autologous stem cell transplantation. We describe the results of a systematic literature review and an explicit approach to consensus techniques, which resulted in recommendations for the management of primary non-APL acute myeloid leukemia.

KW - Acute myeloid leukemia

KW - Clinical practice guidelines

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=58149276410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149276410&partnerID=8YFLogxK

U2 - 10.3324/haematol.13166

DO - 10.3324/haematol.13166

M3 - Article

C2 - 19001282

AN - SCOPUS:58149276410

VL - 94

SP - 102

EP - 112

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -